Last reviewed · How we verify
A Study to Assess the Safety and Pharmacokinetics of Inhaled Doses of GSK233705 and GW642444 in Healthy Subjects
GW642444 and GSK233705 are in development for treatment of Chronic Obstructive Pulmonary Disease. Development of these two inhaled drugs as a combination therapy would have potential for improved patient benefit as they both work through different mechanisms and the combined bronchodilatory effect might be additive. This study will look at the this combination, for the first time, in healthy Japanese subjects.
Details
| Lead sponsor | GlaxoSmithKline |
|---|---|
| Phase | PHASE1 |
| Status | COMPLETED |
| Enrolment | 16 |
| Start date | Mon Nov 10 2008 00:00:00 GMT+0000 (Coordinated Universal Time) |
| Completion | Fri Feb 06 2009 00:00:00 GMT+0000 (Coordinated Universal Time) |
Conditions
- Pulmonary Disease, Chronic Obstructive
Interventions
- GSK233705 and GW642444
- GW642444
- GSK233705
- Placebo
Countries
United Kingdom